Thangam Cancer Centre And Research Institute Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 25-12-2024
- Paid Up Capital ₹ 8.00 M
as on 25-12-2024
- Company Age 9 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -80.34%
(FY 2021)
- Profit 58.75%
(FY 2021)
- Ebitda 58.75%
(FY 2021)
- Net Worth -19.62%
(FY 2021)
- Total Assets -17.22%
(FY 2021)
About Thangam Cancer Centre And Research Institute
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 8.00 M, as per Ministry of Corporate Affairs (MCA) records.
Malliga Mani and Rajalinga Kulandaivel serve as directors at the Company.
- CIN/LLPIN
U85100TZ2015PTC021084
- Company No.
021084
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Jan 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Coimbatore
Industry
Company Details
- Location
Namakkal, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Thangam Cancer Centre And Research Institute?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajalinga Kulandaivel  | Managing Director | 30-Jan-2015 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Malliga Mani | Director | 30-Jan-2015 | Current |
Financial Performance of Thangam Cancer Centre And Research Institute.
Thangam Cancer Centre And Research Institute Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 80.34% decrease. The company also saw a substantial improvement in profitability, with a 58.75% increase in profit. The company's net worth observed a substantial decline by a decrease of 19.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Thangam Cancer Centre And Research Institute?
In 2021, Thangam Cancer Centre And Research Institute had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Thangam Cancer Centre And Research Institute?
Unlock and access historical data on people associated with Thangam Cancer Centre And Research Institute, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Thangam Cancer Centre And Research Institute, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Thangam Cancer Centre And Research Institute's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
